Current Neuro-Oncology
Volume
14 Number 12
31 December 2012
Home > Publications > Current Neuro-Oncology > Volume 14, Year 2012 > Number 12, 31 December
Paulsson
AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ,
Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan
MD.
Limited
Margins Using Modern Radiotherapy Techniques Does Not Increase
Marginal Failure Rate of Glioblastoma.
Am
J Clin Oncol. 2012 Dec 1. 2014;37(2):177-81. doi:
10.1097/COC.0b013e318271ae03🡥.
PMID: 23211224🡥.
Retrospective
analysis. 🡥
Duntze
J, Litré CF, Eap C, Théret E, Debreuve A, Jovenin N,
Lechapt-Zalcman E, Metellus P, Colin P, Guillamo JS, Emery E,
Menei P, Rousseaux P, Peruzzi P.
Implanted
Carmustine Wafers Followed by Concomitant Radiochemotherapy to
Treat Newly Diagnosed Malignant Gliomas: Prospective,
Observational, Multicenter Study on 92 Cases.
Ann
Surg Oncol. 2012 Dec 2. 2013;20(6):2065-72. doi:
10.1245/s10434-012-2764-x🡥.
PMID: 23212763🡥.
Prospective study. 🡥
Leibetseder
A, Ackerl M, Flechl B, Wöhrer A, Widhalm G, Dieckmann K,
Kreinecker SS, Pichler J, Hainfellner J, Preusser M, Marosi
C.
Outcome
and molecular characteristics of adolescent and young adult
patients with newly diagnosed primary glioblastoma: a study of the
Society of Austrian Neurooncology (SANO).
Neuro
Oncol. 2012 Dec 7. 2013;15(1):112-21. doi:
10.1093/neuonc/nos283🡥.
PMID: 23223340🡥.
Retrospective
analysis. 🡥
Wagoner
MP, Roopra A.
A
REST derived gene signature stratifies glioblastomas into
chemotherapy resistant and responsive disease.
BMC
Genomics. 2012 Dec 7;13:686. doi: 10.1186/1471-2164-13-686🡥.
PMID: 23216891🡥.
Laboratory investigation. 🡥
Shibui
S, Narita Y, Mizusawa J, Beppu T, Ogasawara K, Sawamura Y,
Kobayashi H, Nishikawa R, Mishima K, Muragaki Y, Maruyama T,
Kuratsu J, Nakamura H, Kochi M, Minamida Y, Yamaki T, Kumabe T,
Tominaga T, Kayama T, Sakurada K, Nagane M, Kobayashi K, Nakamura
H, Ito T, Yazaki T, Sasaki H, Tanaka K, Takahashi H, Asai A, Todo
T, Wakabayashi T, Takahashi J, Takano S, Fujimaki T, Sumi M,
Miyakita Y, Nakazato Y, Sato A, Fukuda H, Nomura K.
Randomized
trial of chemoradiotherapy and adjuvant chemotherapy with
nimustine (ACNU) versus nimustine plus procarbazine for newly
diagnosed anaplastic astrocytoma and glioblastoma
(JCOG0305).
Cancer
Chemother Pharmacol. 2012 Dec 11. 2013;71(2):511-21. doi:
10.1007/s00280-012-2041-5🡥.
PMID: 23228988🡥.
Phase
2-3 trial. 🡥
Hu
J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG,
Hochberg F.
A
phase II trial of oral gimatecan for recurrent glioblastoma.
J
Neurooncol. 2012 Dec 12. 2013;111(3):347-53. doi:
10.1007/s11060-012-1023-0🡥.
PMID: 23232808🡥.
Phase 2 trial. 🡥
Lomax
AJ, Hill PA, Ashley DM.
Case
report of interstitial nephritis induced by bevacizumab therapy
for glioblastoma multiforme.
J
Oncol Pharm Pract. 2012 Dec 12. 2013;19(4):365-8. doi:
10.1177/1078155212466421🡥.
PMID: 23235917🡥.
Case
report. 🡥
Omuro
A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis
LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C,
Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF,
Mellinghoff I.
Phase
II trial of continuous low-dose temozolomide for patients with
recurrent malignant glioma.
Neuro
Oncol. 2012 Dec 14. 2013;15(2):242-50. doi:
10.1093/neuonc/nos295🡥.
PMID: 23243055🡥.
Phase
2 trial. 🡥
Melguizo
C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ,
Madeddu R, Perazzoli G, Oliver JA, López R,
Rodríguez-Serrano F, Aránega A.
MGMT
promoter methylation status and MGMT and CD133 immunohistochemical
expression as prognostic markers in glioblastoma patients treated
with temozolomide plus radiotherapy.
J
Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250🡥.
PMID: 23245659🡥.
Retrospective analysis. 🡥
Arcella
A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V,
Cantore G, Giangaspero F, Fornai F.
Rapamycin
inhibits the growth of glioblastoma.
Brain
Res. 2012 Dec 19. 2013;1495:37-51. doi:
10.1016/j.brainres.2012.11.044🡥.
PMID: 23261661🡥.
Laboratory
investigation. 🡥
Gutenberg
A, Bock HC, Reifenberger G, Brück W, Giese A.
Toxicity
and survival in primary glioblastoma patients treated with
concomitant plus adjuvant temozolomide versus adjuvant
temozolomide: results of a single-institution, retrospective,
matched-pair analysis.
Acta
Neurochir (Wien). 2012 Dec 20. 2013;155(3):429-35. doi:
10.1007/s00701-012-1583-y🡥.
PMID: 23254891🡥.
Retrospective analysis. 🡥
Hiniker
A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A.
Gliosarcoma
arising from an oligodendroglioma (oligosarcoma).
Clin
Neuropathol. 2012 Dec 20. 2013 May-Jun;32(3):165-70. doi:
10.5414/NP300577🡥.
PMID: 23254140🡥.
Case
report. 🡥
Farace
P, Amelio D, Ricciardi GK, Zoccatelli G, Magon S, Pizzini F,
Alessandrini F, Sbarbati A, Amichetti M, Beltramello A.
Early
MRI changes in glioblastoma in the period between surgery and
adjuvant therapy.
J
Neurooncol. 2012 Dec 22. 2013;111(2):177-85. doi:
10.1007/s11060-012-0997-y🡥.
PMID: 23264191🡥
Retrospective
analysis. 🡥
Lettau
M, Jedrusik P, Laible M.
Dural
Metastases of a Glioblastoma.
Clin
Neuroradiol. 2012 Dec 23. 2013;23(4):323-5. doi:
10.1007/s00062-012-0192-8🡥.
PMID: 23263292🡥.
Case report. 🡥
*
Predina
J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon
EK, Fridlender ZG, Albelda S, Singhal S.
Changes
in the local tumor microenvironment in recurrent cancers may
explain the failure of vaccines after surgery.
Proc
Natl Acad Sci U S A. 2012 Dec 27, 2013;110(5):E415-24🡥.
doi: 10.1073/pnas.1211850110🡥.
PMID: 23271806🡥.
Laboratory
investigation. 🡥